Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial

[1] Lopez-Olivo MA(2015)Rituximab for rheumatoid arthritis Cochrane Database Syst Rev 1 CD007356-278

[2] Amezaga UM(2011)Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Health Technol Assess 15 1-502

[3] McGahan L(2013)Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients Ann Rheum Dis 72 1496-6

[4] Pollono EN(2015)Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years J Rheumatol 42 1761-88

[5] Suarez-Almazor ME(1999)Rituximab Drugs 58 79-11

[6] Malottki K(2001)Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology (Oxford) 40 205-8

[7] Barton P(2002)Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann Rheum Dis 61 883-81

[8] Tsourapas A(2004)Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572-35

[9] Uthman AO(2014)Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis Arthritis Care Res (Hoboken) 66 228-8

[10] Liu Z(2009)Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) Reumatismo 61 306-7

[1] Lopez-Olivo MA(2015)Rituximab for rheumatoid arthritis Cochrane Database Syst Rev 1 CD007356-278

[2] Amezaga UM(2011)Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Health Technol Assess 15 1-502

[3] McGahan L(2013)Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients Ann Rheum Dis 72 1496-6

[4] Pollono EN(2015)Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years J Rheumatol 42 1761-88

[5] Suarez-Almazor ME(1999)Rituximab Drugs 58 79-11

[6] Malottki K(2001)Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology (Oxford) 40 205-8

[7] Barton P(2002)Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann Rheum Dis 61 883-81

[8] Tsourapas A(2004)Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572-35

[9] Uthman AO(2014)Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis Arthritis Care Res (Hoboken) 66 228-8

[10] Liu Z(2009)Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) Reumatismo 61 306-7